Holen Sie sich die Stockscreener-App
1.91
7.28%
-0.15
Handel nachbörslich:
1.90
-0.01
-0.52%
Schlusskurs vom Vortag:
$2.06
Offen:
$2.06
24-Stunden-Volumen:
544.66K
Relative Volume:
0.25
Marktkapitalisierung:
$6.16M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-23.72M
KGV:
-0.0196
EPS:
-97.2514
Netto-Cashflow:
$-23.28M
1W Leistung:
-11.98%
1M Leistung:
-36.33%
6M Leistung:
-97.38%
1J Leistung:
-99.29%
1-Tages-Spanne:
$1.86
$2.06
1-Wochen-Bereich:
$1.86
$2.26
52-Wochen-Spanne:
$1.86
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Vergleichen Sie APVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.91 | 6.64M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo highlights prostate cancer bispecific antibody candidate By Investing.com - Investing.com Nigeria
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - ACCESS Newswire
Aptevo's New Prostate Cancer Drug Shows Promise with Targeted Immune Response Technology - Stock Titan
Aptevo Therapeutics APVO Q2 2025 Earnings Preview Downside Risk Over Lack of Revenue Growth - AInvest
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Inc. SEC 10-Q Report - TradingView
Aptevo Reports 85% Remission in Q2 - The Motley Fool
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - ACCESS Newswire
Aptevo Reports Breakthrough: 85% Remission in AML Trial, Launches New Solid Tumor Program - Stock Titan
Evaluating Aptevo Therapeutics Inc. with trendline analysisReal Time Trade Execution Alert Plan - Newser
Is Aptevo Therapeutics Inc. likely to announce a buybackBest ROI Stocks This Month - sisain.net
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionWeekly Chart Watchlist with Trade Guidance - Newser
Historical volatility pattern of Aptevo Therapeutics Inc. visualizedRisk-Managed Swing Setup and Signal Analysis - Newser
Using data models to predict Aptevo Therapeutics Inc. stock movementSafe Entry Screening with Data Backed Analysis - Newser
Aptevo Therapeutics Inc expected to post a loss of $83.20 a shareEarnings Preview - TradingView
Aptevo Therapeutics and 60 Degrees Pharmaceuticals to be Featured on Bloomberg TV's RedChip Small Stocks, Big Money Show - AInvest
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Corinthian
Aptevo Therapeutics (APVO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Multi factor analysis applied to Aptevo Therapeutics Inc.Real Chart Based Opportunity Identification - Newser
How volatile is Aptevo Therapeutics Inc. stock compared to the marketDiscover top stock picks for aggressive growth - Jammu Links News
What institutional investors are buying Aptevo Therapeutics Inc. stockMaximize portfolio value with timely trades - Jammu Links News
Is Aptevo Therapeutics Inc. a good long term investmentMaximize portfolio growth with expert advice - Jammu Links News
How does Aptevo Therapeutics Inc. generate profit in a changing economyDiscover undervalued stocks ready to soar - Jammu Links News
How does Aptevo Therapeutics Inc. compare to its industry peersDiscover high-impact stocks for your portfolio - Jammu Links News
Is it the right time to buy Aptevo Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
How strong is Aptevo Therapeutics Inc. company’s balance sheetBuild a portfolio for long-term financial success - Jammu Links News
Why is Aptevo Therapeutics Inc. stock attracting strong analyst attentionCapitalize on emerging growth stocks - Jammu Links News
Does Aptevo Therapeutics Inc. stock perform well during market downturnsTremendous wealth creation - Jammu Links News
When is Aptevo Therapeutics Inc. stock expected to show significant growthInvest smarter with actionable market insights - Jammu Links News
What drives Aptevo Therapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for Aptevo Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Aptevo Therapeutics Inc. stock in 2025Unlock your trading potential today - Jammu Links News
What are Aptevo Therapeutics Inc. company’s key revenue driversBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Aptevo Therapeutics Inc.Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Aptevo Therapeutics Inc. Shows Support at Fibonacci LevelFree Elite Traders Group - beatles.ru
What is Aptevo Therapeutics Inc. company’s growth strategyInvest smarter with advanced market data - Jammu Links News
Is Aptevo Therapeutics Inc. a Top Dividend Stock to Watch in 2025Top Gaining Low Risk Assets - metal.it
Is Aptevo Therapeutics Inc. a growth stock or a value stockTransform your portfolio with high-yield stocks - jammulinksnews.com
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):